Literature DB >> 12562457

Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects.

A Cats1, E J Kuipers, M A R Bosschaert, R G J Pot, C M J E Vandenbroucke-Grauls, J G Kusters.   

Abstract

BACKGROUND: Several studies have reported inhibitory effects of lactic acid bacteria on bacterial pathogens. AIM: To test whether a drink containing Lactobacillus casei strain Shirota inhibits Helicobacter pylori growth.
METHODS: The in vitro growth inhibition of H. pylori was studied when L. casei was added to plates previously inoculated with H. pylori reference strain NCTC 11637. In an intervention study, 14 H. pylori-positive subjects were given Yakult drink (10(8) colony-forming units/mL L. casei) thrice daily during meals for 3 weeks. Six untreated H. pylori-positive subjects served as controls. H. pylori bacterial loads were determined using the 13C-urea breath test, which was performed before and 3 weeks after the start of L. casei supplementation.
RESULTS: In vitro, L. casei inhibits H. pylori growth. This effect was stronger with L. casei grown in milk solution than in DeMan-Rogosa-Sharpe medium. No growth inhibition was shown with medium inoculated with lactic acid, Escherichia coli strain DH5alpha or uninoculated medium. Filtration of L. casei culture before incubation with H. pylori completely abolished the inhibitory effect. Urease activity decreased in nine of the 14 (64%) subjects with L. casei supplementation and in two of the six (33%) controls (P = 0.22).
CONCLUSIONS: Viable L. casei are required for H. pylori growth inhibition. This does not result from changes in lactic acid concentration. In addition, a slight, but non-significant, trend towards a suppressive effect of L. casei on H. pylori in vivo may exist.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12562457     DOI: 10.1046/j.1365-2036.2003.01452.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  30 in total

1.  Bacteriocin production by strain Lactobacillus delbrueckii ssp. bulgaricus BB18 during continuous prefermentation of yogurt starter culture and subsequent batch coagulation of milk.

Authors:  E D Simova; D M Beshkova; M P Angelov; Zh P Dimitrov
Journal:  J Ind Microbiol Biotechnol       Date:  2008-02-14       Impact factor: 3.346

2.  Lactobacillus johnsonii La1 attenuates Helicobacter pylori-associated gastritis and reduces levels of proinflammatory chemokines in C57BL/6 mice.

Authors:  Dionyssios N Sgouras; Effrosini G Panayotopoulou; Beatriz Martinez-Gonzalez; Kalliopi Petraki; Spyros Michopoulos; Andreas Mentis
Journal:  Clin Diagn Lab Immunol       Date:  2005-12

3.  Peptide Extracts from Cultures of Certain Lactobacilli Inhibit Helicobacter pylori.

Authors:  Luc De Vuyst; Pascal Vincent; Eleftherios Makras; Frédéric Leroy; Bruno Pot
Journal:  Probiotics Antimicrob Proteins       Date:  2010-03       Impact factor: 4.609

4.  Novel perspectives in probiotic treatment: the efficacy and unveiled mechanisms of the physiological functions.

Authors:  Mikihiro Fujiya; Yutaka Kohgo
Journal:  Clin J Gastroenterol       Date:  2010-05-08

Review 5.  Efficacy of fermented milk and whey proteins in Helicobacter pylori eradication: a review.

Authors:  Aarti Sachdeva; Swapnil Rawat; Jitender Nagpal
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

Review 6.  Probiotics for the treatment of Helicobacter pylori infection in children.

Authors:  Lucia Pacifico; John Frederick Osborn; Enea Bonci; Sara Romaggioli; Rossella Baldini; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

7.  Lactic acid bacterial extracts as anti-Helicobacter pylori: a molecular approach.

Authors:  H El-Adawi; M El-Sheekh; M Khalil; N El-Deeb; M Hussein
Journal:  Ir J Med Sci       Date:  2013-02-13       Impact factor: 1.568

8.  In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota.

Authors:  D Sgouras; P Maragkoudakis; K Petraki; B Martinez-Gonzalez; E Eriotou; S Michopoulos; G Kalantzopoulos; E Tsakalidou; A Mentis
Journal:  Appl Environ Microbiol       Date:  2004-01       Impact factor: 4.792

9.  Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome.

Authors:  Na Young Lee; Sang Jun Yoon; Dae Hee Han; Haripriya Gupta; Gi Soo Youn; Min Jea Shin; Young Lim Ham; Min Jung Kwak; Byung Yong Kim; Jeong Seok Yu; Do Yup Lee; Tae-Sik Park; Si-Hyun Park; Byoung Kook Kim; Hyun Chae Joung; In Suk Choi; Ji Taek Hong; Dong Joon Kim; Sang Hak Han; Ki Tae Suk
Journal:  Gut Microbes       Date:  2020-01-22

Review 10.  Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.